Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Lyell Immunopharma (LYEL) Assets Average: 2021-2025

Historic Assets Average for Lyell Immunopharma (LYEL) over the last 4 years, with Sep 2025 value amounting to $396.7 million.

  • Lyell Immunopharma's Assets Average fell 37.69% to $396.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.7 million, marking a year-over-year decrease of 37.69%. This contributed to the annual value of $620.4 million for FY2024, which is 26.47% down from last year.
  • Per Lyell Immunopharma's latest filing, its Assets Average stood at $396.7 million for Q3 2025, which was down 2.68% from $407.6 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Assets Average ranged from a high of $1.2 billion in Q3 2021 and a low of $396.7 million during Q3 2025.
  • Moreover, its 3-year median value for Assets Average was $674.2 million (2024), whereas its average is $655.2 million.
  • Data for Lyell Immunopharma's Assets Average shows a maximum YoY plummeted of 39.54% (in 2025) over the last 5 years.
  • Lyell Immunopharma's Assets Average (Quarterly) stood at $1.2 billion in 2021, then decreased by 17.67% to $957.4 million in 2022, then decreased by 19.31% to $772.5 million in 2023, then fell by 28.15% to $555.0 million in 2024, then slumped by 37.69% to $396.7 million in 2025.
  • Its last three reported values are $396.7 million in Q3 2025, $407.6 million for Q2 2025, and $460.3 million during Q1 2025.